RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050

RealRate

July 10, 2026

To the CEO
SIGA Technologies INC
31 EAST 62ND STREET
NEW YORK, NY 10065
USA

SIGA Technologies INC TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that SIGA Technologies INC has been TOP Rated at rank 6 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at https://www.realrate.ai/rankings. Your individual rating report, showing your strengths compared to your competitors is attached.

TOP RATED 2026 RealRate

SIGA Human BioArmor®

RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just $9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: https://calendly.com/holger-bartel

Sincerely,

Dr. Holger Bartel, CEO

holger.bartel@realrate.ai • www.realrate.ai • +49 160 957 90 844

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for SIGA Technologies INC. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.

RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by SIGA Technologies INC (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	**2026 US Pharmaceutical RealRate rating seal for SIGA Technologies INC**
Amount	**USD 9,900**
Order no.	2026-0001010086

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address

Company name		Full name	
Street address		Department	
City		Phone number	
State / provice		Email address	
ZIP code			
Country			

Shipping address
The electronic RealRate rating seal and the invoice will be sent to

Delivery email	

SIGA Technologies INC

Date, location, name

PHARMACEUTICAL 2026

SIGA Technologies INC
Rank 6 of 178



PHARMACEUTICAL 2026

SIGA Technologies INC
Rank 6 of 178

The relative strengths and weaknesses of SIGA Technologies INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SIGA Technologies INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 140% points.The greatest weakness of SIGA Technologies INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 425%, being 195% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	212,857
Cost of Goods Sold	29,704
Intangible Assets	898
Liabilities, Current	17,993
Liabilities, Non-Current	2,653
Other Assets	4,621
Other Compr. Net Income	0
Other Expenses	7,103
Other Liabilities	0
Other Net Income	6,680
Other Revenues	94,575
Property and Equipment	1,091
Research and Development	19,956
Selling, General and Administrative Expense	21,213

Output Variable	Value in 1000 USD
Assets	219,467
Liabilities	20,646
Expenses	77,976
Revenues	94,575
Stockholders Equity	198,822
Net Income	23,279
Comprehensive Net Income	23,279
BaseVar	209,672
ECR before LimitedLiability	380%
Economic Capital Ratio	425%